These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36309653)

  • 1. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
    Davis SL; Hartman SJ; Bagby SM; Schlaepfer M; Yacob BW; Tse T; Simmons DM; Diamond JR; Lieu CH; Leal AD; Cadogan EB; Hughes GD; Durant ST; Messersmith WA; Pitts TM
    BMC Cancer; 2022 Oct; 22(1):1107. PubMed ID: 36309653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells.
    Wang Y; Yang L; Zhang J; Zhou M; Shen L; Deng W; Liang L; Hu R; Yang W; Yao Y; Zhang H; Zhang Z
    Int J Oncol; 2018 Oct; 53(4):1667-1680. PubMed ID: 30085332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
    Vitiello PP; Martini G; Mele L; Giunta EF; De Falco V; Ciardiello D; Belli V; Cardone C; Matrone N; Poliero L; Tirino V; Napolitano S; Della Corte C; Selvaggi F; Papaccio G; Troiani T; Morgillo F; Desiderio V; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2021 Jan; 40(1):15. PubMed ID: 33407715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
    Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
    BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
    Riches LC; Trinidad AG; Hughes G; Jones GN; Hughes AM; Thomason AG; Gavine P; Cui A; Ling S; Stott J; Clark R; Peel S; Gill P; Goodwin LM; Smith A; Pike KG; Barlaam B; Pass M; O'Connor MJ; Smith G; Cadogan EB
    Mol Cancer Ther; 2020 Jan; 19(1):13-25. PubMed ID: 31534013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts.
    Scheper J; Hildebrand LS; Faulhaber EM; Deloch L; Gaipl US; Symank J; Fietkau R; Distel LV; Hecht M; Jost T
    Strahlenther Onkol; 2023 Dec; 199(12):1128-1139. PubMed ID: 36229655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
    Jones GN; Rooney C; Griffin N; Roudier M; Young LA; Garcia-Trinidad A; Hughes GD; Whiteaker JR; Wilson Z; Odedra R; Zhao L; Ivey RG; Howat WJ; Harrington EA; Barrett JC; Ramos-Montoya A; Lau A; Paulovich AG; Cadogan EB; Pierce AJ
    Br J Cancer; 2018 Nov; 119(10):1233-1243. PubMed ID: 30385821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the ATM inhibitor AZD0156 on the radiosensitivity of human breast cancer and lung fibroblast cells.
    Yilmaz U; Kamer D; Asik A; Kara HG; Gündüz C; Kamer S
    J Cancer Res Ther; 2023; 19(2):203-207. PubMed ID: 37006058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
    Marks EI; Matera R; Olszewski AJ; Yakirevich E; El-Deiry WS; Safran H; Carneiro BA
    Am J Clin Oncol; 2021 Feb; 44(2):68-73. PubMed ID: 33298767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP5: A Novel Therapeutic Approach Targeting Aberrant and Hyperactive CDK5/p25 for the Treatment of Colorectal Carcinoma.
    Amin N; Wang H; Song Q; Bhaskar M; Yadav SP; Gilbert MR; Pant H; Tabouret E; Zhuang Z
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5‑fluorouracil by inhibiting repair of DNA damage.
    Suzuki T; Hirokawa T; Maeda A; Harata S; Watanabe K; Yanagita T; Ushigome H; Nakai N; Maeda Y; Shiga K; Ogawa R; Mitsui A; Kimura M; Matsuo Y; Takahashi H; Takiguchi S
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35191521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
    Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
    Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
    Crea F; Giovannetti E; Cortesi F; Mey V; Nannizzi S; Gallegos Ruiz MI; Ricciardi S; Del Tacca M; Peters GJ; Danesi R
    Mol Cancer Ther; 2009 Jul; 8(7):1964-73. PubMed ID: 19531575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.
    Koneru B; Farooqi A; Nguyen TH; Chen WH; Hindle A; Eslinger C; Makena MR; Burrow TA; Wilson J; Smith A; Pilla Reddy V; Cadogan E; Durant ST; Reynolds CP
    Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34408079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
    Plasencia C; Abad A; Martinez-Balibrea E; Taron M
    Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Cancer Res Treat; 2020 Jan; 52(1):149-166. PubMed ID: 31291716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caffeine enhances chemosensitivity to irinotecan in the treatment of colorectal cancer.
    Yoon S; Lee BK; Kim KP
    Phytomedicine; 2023 Dec; 121():155120. PubMed ID: 37806154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models.
    Jin WJ; Zangl LM; Hyun M; Massoud E; Schroeder K; Alexandridis RA; Morris ZS
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
    Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
    Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single protein encapsulated SN38 for tumor-targeting treatment.
    Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
    J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.